BioLife Solutions (BLFS +1.5%) exercised its option to acquire the remaining 56% stake in privately held SAVSU Technologies in exchange for 1.1M BioLife shares.
The acquisition broadens BioLife’s bioproduction tools portfolio and increases its footprint and engagement level in its customers’ cell and gene therapy manufacturing, storage and distribution workflows.
The company will revise its financial outlook during Q2 2019 earnings call, scheduled on August 8, 2019
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.